Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 44Carcinoma, Hepatocellular 42Small Cell Lung Carcinoma 28Breast Neoplasms 18Cholangiocarcinoma 17Urinary Bladder Neoplasms 16Biliary Tract Neoplasms 15Liver Neoplasms 13Neoplasms 12Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 9Carcinoma 9Squamous Cell Carcinoma of Head and Neck 8Endometrial Neoplasms 7Colorectal Neoplasms 7Stomach Neoplasms 6Carcinoma, Transitional Cell 6Melanoma 5Gallbladder Neoplasms 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasms by Site 4Mesothelioma 4

Interventions

pembrolizumab 1osimertinib 1durvalumab 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non Small Cell Lung Cancer × durvalumab × 1 year × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡